Cargando…
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy
Elderly patients are recommended to have a reduced starting dose (300 mg m(−2) once every 3 weeks) of irinotecan monotherapy. The aims of this analysis are to compare toxicity and survival according to age, performance status (PS), gender and prior radical pelvic radiotherapy (RT). The primary end p...
Autores principales: | Chau, I, Norman, A R, Cunningham, D, Waters, J S, Topham, C, Middleton, G, Hill, M, Ross, P J, Katopodis, R, Stewart, G, Oates, J R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409923/ https://www.ncbi.nlm.nih.gov/pubmed/15365570 http://dx.doi.org/10.1038/sj.bjc.6602169 |
Ejemplares similares
-
Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants
por: Raber, Inbar, et al.
Publicado: (2020) -
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing
por: Patel, Kalpesh, et al.
Publicado: (2012) -
Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991) -
Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy
por: Pereira, Marina Alessandra, et al.
Publicado: (2018) -
The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population
por: Abbasian, Mohammad Hadi, et al.
Publicado: (2020)